Personalized dosing for late-stage prostate cancer treatments is critical for balancing toxicity with aggressiveness. Yet, dose-prediction models are either fast but inaccurate or accurate but too slow to be clinically useful. A June study published in IEEE Transactions on Radiation and Plasma Medical Sciences described DiffuDose, a fast AI-biomedical tool that combines the best of both: speed and accuracy.
Prostate cancer is the second deadliest cancer in men in the United States. If caught early, prostate cancer is treatable with a 99 percent five-year survival rate. But if caught late and the cancer has spread to other parts of the body, including the liver, lungs, or bones, the survival rates drop significantly.
In 2022, radiopharmaceutical therapy was approved for use in late-stage prostate cancer patients. Radiopharmaceutical therapy is an injection that uses a cancer-detecting molecule to direct radiation to cancer cells around the body, making it a critical treatment for metastatic cancer.
Radiopharmaceutical therapy helps track disease progression because the treatment's radiation emits gamma rays. These rays can be imaged with a SPECT scanner, similar to a PET or CT scann...